Managing Risks with Newer Oral Small Molecules in Patients with IBD

What are the risks of treating inflammatory bowel diseases (IBD) with small oral molecules, JAK inhibitors, and Sphingosine-1-phosphate receptor modulators, and how should they be managed? In this MEDtalk, Dr. Parakkal Deepak presents his insights, published in a recent article in Current Gastroenterology Reports. He especially highlighted major adverse cardiac events and the importance of discussing this with patients.